Quote this publication Share Print

HERCEPTIN (trastuzumab), monoclonal antibody - GASTRIC CANCER

ONCOLOGY - Investigation
Opinions on drugs - Posted on Sep 28 2016

Reason for request

Re-assessment of the actual benefit and the improvement in actual benefit

Minor improvement in combination with chemotherapy in the treatment of metastatic HER2+ gastric or gastro-oesophageal junction cancer

  • HERCEPTIN has Marketing Authorisation in the treatment of metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with tumour HER2 overexpression, in combination with fluoropyrimidine (5FU or capecitabine) and cisplatin, in patients who have not been previously treated for their metastatic disease.
  • In the only available comparative study, its addition to chemotherapy was associated with a modest benefit in terms of median overall survival (gain of 4.2 months) without benefit in quality of life. No new clinical data confirmed these results, resulting from a post-hoc subgroup analysis.
  • The only targeted therapy available in this indication, it is nevertheless the standard treatment in combination with chemotherapy.

Actual benefit



Improvement in actual benefit

IV (mineur)


Therapeutic use


Contact Us

Évaluation des médicaments